Germline mutations of DNA homologous recombination repair (HRR) genes, particularly BRCA2, are frequently found in advanced prostate cancers (PCs) [1,2], and predict poor outcomes for conventional therapies [3,4,5,6]. The gene discussed is BRCA2; the disease is Familial prostate cancer.